Vedolizumab Efficacy, Safety, and Pharmacokinetics With Reduced Frequency of Dosing From Every 4 Weeks to Every 8 Weeks in Patients With Crohn's Disease or Ulcerative Colitis
Articolo
Data di Pubblicazione:
2020
Citazione:
Vedolizumab Efficacy, Safety, and Pharmacokinetics With Reduced Frequency of Dosing From Every 4 Weeks to Every 8 Weeks in Patients With Crohn's Disease or Ulcerative Colitis / Vermeire, Séverine; Lukáš, Milan; Magro, Fernando; Adsul, Shashi; Lindner, Dirk; Rosario, Maria; Roth, Jeannine; Danese, Silvio. - In: JOURNAL OF CROHN'S AND COLITIS. - ISSN 1873-9946. - 14:8(2020), pp. 1066-1073-1073. [10.1093/ecco-jcc/jjaa027]
Abstract:
Vedolizumab was shown to be safe and effective for the treatment of Crohn's disease [CD] and ulcerative colitis [UC] in the GEMINI Long-Term Safety [LTS] study. The vedolizumab Extended Access Program [XAP] provides patients with continued treatment. This XAP pharmacokinetics [PK] sub-study investigated vedolizumab efficacy, safety, and PK.
Tipologia CRIS:
1.1 Articolo in rivista
Keywords:
Clinical trials; Crohn’s disease; Vedolizumab; ulcerative colitis
Elenco autori:
Vermeire, Séverine; Lukáš, Milan; Magro, Fernando; Adsul, Shashi; Lindner, Dirk; Rosario, Maria; Roth, Jeannine; Danese, Silvio
Link alla scheda completa:
Pubblicato in: